America’s patent system isn’t broken — so it doesn’t need “fixing”
Dr. Rachel Goode, an executive at a German generic pharmaceutical company, recently argued that “brand-name drug companies are gaming the [U.S.] patent system” by filing duplicative patents meant to block generics manufacturers from entering the market with cheaper copy-cat treatments. But there’s scant evidence to support that claim. Brand-name drugmakers file patents at a rate